Assessment of free dye in solutions of dual-labeled antibody conjugates for in vivo molecular imaging

Molecular Imaging and Biology

Volumn 13, Issue 1, 2011, Pages 32-42

  Aldrich, Melissa B ^a   Wang, Xuejuan ^a   Hart, Amy ^a   Kwon, Sunkuk ^a   Sampath, Lakshmi ^a   Marshall, Milton V ^a   Sevick Muraca, Eva M ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

CV (coefficient of variation); DTPA (diethylenetriaminepentaacetic acid); HPLC (high performance liquid chromatography); IRDye 800CW; NIR (near infrared); SEC (size exclusion chromatography); TLC (thin layer chromatography)

Indexed keywords

IRDYE 800 TRASTUZUMAB PENTETATE INDIUM IN 111; RADIOISOTOPE; UNCLASSIFIED DRUG;

ACCURACY; ANTIBODY LABELING; ARTICLE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; MOLECULAR IMAGING; NEAR INFRARED REFLECTANCE SPECTROSCOPY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY;

ANTIBODIES, MONOCLONAL; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLORING AGENTS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; INDICATORS AND REAGENTS; INDIUM RADIOISOTOPES; LIMIT OF DETECTION; PENTETIC ACID; SOLUTIONS; SPECTROSCOPY, NEAR-INFRARED;

EID: 79551587566     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-010-0328-7     Document Type: Article

References (34)

1. EM Sevick-Muraca R Sharma JC Rasmussen MV Marshall JA Wendt HQ Pham E Bonefas JP Houston L Sampath KE Adams DK Blanchard RE Fisher SB Chiang R Elledge ME Mawad 2008 Imaging of lymph flow in breast cancer patients after microdose administration of a near-infrared fluorophore: feasibility study Radiology 246 3 734 741 10.1148/radiol.2463070962 18223125
2. JC Rasmussen IC Tan MV Marshall CE Fife EM Sevick-Muraca 2009 Lymphatic imaging in humans with near-infrared fluorescence Curr Opin Biotechnol 20 1 74 82 1:CAS:528:DC%2BD1MXlslWgsrc%3D 10.1016/j.copbio.2009.01.009 19233639
3. Meyers CLF, Meyers DJ (2008) Thin-layer chromatography. In: Curr Protoc Nucleic Acid Chem. Wiley, 34:A.3D.1-A.3D.13
4. B Dhesy-Thind KI Pritchard H Messersmith F O'Malley L Elavathil M Trudeau 2008 HER2/neu in systemic therapy for women with breast cancer: a systematic review Breast Cancer Res Treat 109 2 209 229 1:CAS:528:DC%2BD1cXlsV2ntrs%3D 10.1007/s10549-007-9656-y 17636396
5. S Menard M Casalini SM Campiglio SM Pupa E Tagliabue 2004 Role of HER2/neu in tumor progression and therapy Cell Mol Life Sci 61 23 2965 2978 1:CAS:528:DC%2BD2MXot1agtQ%3D%3D 10.1007/s00018-004-4277-7 15583858
6. R Nanda 2007 Targeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directions Rev Recent Clin Trials 2 2 111 116 1:CAS:528:DC%2BD2sXms1Oisr0%3D 10.2174/157488707780599375 18473995
7. A Lin HS Rugo 2007 The role of trastuzumab in early stage breast cancer: current data and treatment recommendations Curr Treat Options Oncol 8 1 47 60 10.1007/s11864-007-0008-2 17660958
8. GN Hortobagyi 2001 Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer Semin Oncol 28 6 Suppl 18 43 47 1:CAS:528:DC%2BD38XhtFOitLc%3D 10.1053/sonc.2001.29710 11774205
9. SC Wang MC Hung 2001 HER2 overexpression and cancer targeting Semin Oncol 28 5 Suppl 16 115 124 1:CAS:528:DC%2BD3MXpt1Wnsr0%3D 10.1016/S0093-7754(01) 90289-1 11706403
10. P Carter L Presta CM Gorman JB Ridgway D Henner WL Wong AM Rowland C Kotts ME Carver HM Shepard 1992 Humanization of an anti-p185HER2 antibody for human cancer therapy Proc Natl Acad Sci USA 89 10 4285 4289 1:CAS:528: DyaK3sXitFSqtb0%3D 10.1073/pnas.89.10.4285 1350088
11. E Tokunaga E Oki K Nishida T Koga A Egashira M Morita Y Kakeji Y Maehar 2006 Trastuzumab and breast cancer: developments and current status Int J Clin Oncol 11 3 199 208 1:CAS:528:DC%2BD28XntVGju7k%3D 10.1007/s10147-006-0575-4 16850126
12. CH Yeon MD Pegram 2005 Anti-erB-2 antibody trastuzumab in the treatment of HER2-amplified cancer Invest New Drugs 23 5 391 409 1:CAS:528: DC%2BD2MXnvVSqsbc%3D 10.1007/s10637-005-2899-8 16133791
13. R Simon A Nocito T Hubscher C Bucher J Torhorst P Schraml L Bubendorf MM Mihatsch H Moch K Wilber A Schotzau J Kononen G Sauter 2001 Patterns of HER-2/neu amplification and overexpression in primary and metastatic breast cancer J Natl Cancer Inst 93 15 1141 1146 1:CAS:528:DC%2BD3MXmtVGqsLc%3D 10.1093/jnci/93.15.1141 11481385
14. SE Order WD Bloomer AG Jones WD Kaplan MA Davis SJ Adelstein S Hellman 1975 Radionuclide immunoglobulin lymphangiography: a case report Cancer 35 6 1487 1492 1:STN:280:DyaE2M3gslWjtA%3D%3D 10.1002/1097-0142(197506)35:6<1487:: AID-CNCR2820350602>3.0.CO;2-E 50121
15. JJ Tjandra IS Russell JP Collins JT Andrews M Lichtenstein D Binns IF McKenzie 1989 Immunolymphoscintigraphy for the detection of lymph node metastases from breast cancer Cancer Res 49 6 1600 1608 1:STN:280: DyaL1M7mvVWqtg%3D%3D 2647290
16. FH DeLand EE Kim DM Goldenberg 1980 Lymphoscintigraphy with radionuclide-labeled antibodies to carcinoembryonic antigen Cancer Res 40 8 Pt. 2 2997 3000 1:STN:280:DyaL3c3ktl2ksA%3D%3D 7397695
17. MT Lotze JA Carrasquillo JN Weinstein GJ Bryant P Perentesis JC Reynolds LA Matis RR Eger AM Keenan I Hellstrom K Hellstrom SM Larson 1986 Monoclonal antibody imaging of human melanoma. Radioimmunodetection by subcutaneous or systemic injection Ann Surg 204 3 223 235 1:STN:280:DyaL28zit1Wgsw%3D%3D 10.1097/00000658-198609000-00002 3753057
18. BL Engelstad LE Spitler MJ Del Rio EC Ramos LL Rosendorf CE Reinhold A Khentigan JP Huberty SW Corpuz HM Lee MD Okerlund RS Hattner PJ Scannon 1986 Phase 1 immunolymphoscintigraphy with an In-111-labeled antimelanoma monoclonal antibody Radiology 161 2 419 422 1:STN:280:DyaL2s%2FhslOisA%3D%3D 3763912
19. WB Nelp JR Eary RF Jones KE Hellstrom I Hellstrom PL Beaumier KA Krohn 1987 Preliminary studies of monoclonal antibody lymphoscintigraphy in malignant melanoma J Nucl Med 28 1 34 41 1:STN:280:DyaL2s%2FosFOqug%3D%3D 3794810
20. 111In-labeled T101 monoclonal antibody in patients with cutaneous T-cell lymphoma Cancer Res 47 22 6093 6099 1:STN:280:DyaL1c%2Fis1yjsw%3D%3D 3499222
21. AM Keenen JN Weinstein JL Mulshine JA Carrasquillo PA Bunn Jr JC Reynolds SM Larson 1987 Immunolymphoscintigraphy in patients with lymphoma after subcutaneous injection of indium-111-labeled T101 monoclonal antibody J Nucl Med 28 1 42 46
22. RL Wahl O Geatti M Liebert B Wilson P Shreve BA Beers 1987 Kinetics of interstitially administered monoclonal antibodies for purposes of lymphoscintigraphy J Nucl Med 28 11 1736 1744 1:STN:280:DyaL1c%2FjsFagsQ%3D%3D 3668665
23. JL Mulshine AM Keenan JA Carrasquillo T Walsh RI Linnoila OD Holton J Harwell SM Larson PA Bunn JN Weinstein 1987 Immunolymphoscintigraphy of pulmonary and mediastinal lymph nodes in dogs: a new approach to lung cancer imaging Cancer Res 47 13 3572 3576 1:STN:280:DyaL2s3hsFKrsQ%3D%3D 3472655
24. KJ Kairemo 1990 Immunolymphoscintigraphy with 99mTc-labeled monoclonal antibody (BW 431/26) reacting with carcinoembryonic antigen in breast cancer Cancer Res 50 3 Suppl. 949s 954s 1:STN:280:DyaK3c7isVaqtA%3D%3D 2297747
25. 111In-labeled monoclonal antibody PAY 276 for the detection of pelvic nodal metastases in prostatic carcinoma Eur J Nucl Med 16 3 149 156 1:STN:280:DyaK3czgs1SksQ%3D%3D 10.1007/BF01146853 2364957
26. 111In and 90Y using a bifunctional DTPA chelating agent Cancer Biother Radiopharm 18 3 355 363 1:CAS:528: DC%2BD3sXmsF2jtr8%3D 10.1089/108497803322285107 12954122
27. Y Tang J Wang DA Scollard H Mondal C Holloway HJ Kahn RM Reilly 2005 Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using (111)In-trastuzumab (Herceptin) Fab fragments Nucl Med Biol 32 1 51 58 1:CAS:528:DC%2BD2MXhtVyisbc%3D 10.1016/j.nucmedbio.2004.08.003 15691661
28. Y Tang D Scollard P Chen J Wang C Holloway RM Reilly 2005 Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments Nucl Med Commun 26 5 427 432 1:CAS:528:DC%2BD2MXjtlKks7s%3D 10.1097/00006231-200505000-00006 15838425
29. EM Sevick-Muraca W Wang L Sampath 2008 Near infrared fluorescent optical imaging for nodal staging J Biomed Opt 13 4 041312 10.1117/1.2953185 19021320
30. EM Sevick-Muraca MV Marshall KE Adams JC Rasmussen JA Wendt R Sharma 2008 New horizons for imaging lymphatic function Ann N TY Acad Sci 1131 13 36 10.1196/annals.1413.002
31. JC Rasmussen EM Sevick-Muraca 2008 Molecular imaging with optics: primer and case for near-infrared fluorescence techniques in personalized medicine J Biomed Opt 13 4 041303 10.1117/1.2953185 19021311
32. L Sampath S Kwon S Ke W Wang R Schiff ME Mawad EM Sevick-Muraca 2007 Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer J Nucl Med 48 9 1501 1510 1:CAS:528:DC%2BD2sXhtFGgsLjE 10.2967/jnumed.107.042234 17785729
33. Guideline for validation of analytical procedures: text and methodology Q2(R1). Current step 4 version. Parent guideline dated 27 October 1994. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. http://www.ich.org/LOB/media/ MEDIA417.pdf
34. Guidance for industry, bioanalytical method validation. US Department of Health and Human Services FDA (CDER) and (CVM), May 2001. http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf